Domestic price of bosutinib

Bosutinib (Bosutinib) is an orally active dual Src/Abl tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) that is resistant/intolerant to previous treatments. Currently reports 2-year follow-up data of a Phase 1/2 open-label study, which evaluated the efficacy and safety of bosutinib as second-line treatment in 288 patients with imatinib-resistant (n=200) or intolerant (n=88) chronic-phase CML.

Cumulative response rates with bosutinib were as follows: 85% achieved/maintained a complete hematologic response, 59% achieved/maintained a major cytogenetic response (including 48% with a complete cytogenetic response), and 35% achieved a major molecular response. Response was durable, with a 2-year estimate of retention of response >70%. The two-year probabilities of progression-free survival and overall survival were 81% and 91%, respectively. The most common toxicities are mainly gastrointestinal adverse events, including diarrhea, nausea, and vomiting, which are mainly mild to moderate, usually transient, and first occur early in treatment. Thrombocytopenia is the most common grade 3/4 hematology laboratory abnormality. Outcomes in patients with imatinib resistance and imatinib intolerance were generally similar and did not differ with age.

The originator drug of bosutinib is not marketed in the country, so it cannot be included in medical insurance. Currently, the original drugs sold overseas include Turkish version and European version. The price of the Turkish version may be more than RMB 2,000 per box of 500mg*28, and the price of the European version may be more than RMB 30,000 (the price may fluctuate due to the exchange rate). There are also bosutinib generic drugs produced overseas in other countries. Their pharmaceutical ingredients are basically the same as those of the original drug. The price of 500mg*30 per box may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.